Davis Polk Advises iKang Healthcare on Its Acquisition by Yunfeng Capital and Alibaba
Davis Polk is advising iKang Healthcare Group, Inc. in connection with its acquisition for $41.20 per common share or $20.60 per American Depository Share by a consortium consisting of certain funds affiliated with Yunfeng Capital, Alibaba Group Holding Limited and certain of iKang’s senior management. The transaction is subject to customary closing conditions, including approval by the shareholders of iKang and is expected to close in the third quarter of 2018.